XBiotech
XBIT
31 hedge funds and large institutions have $8.18M invested in XBiotech in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 16 reducing their positions, and 17 closing their positions.
3.79% less ownership
Funds ownership: 8.93% → 5.14% (-3.8%)
28% less funds holding
Funds holding: 43 → 31 (-12)
51% less call options, than puts
Call options by funds: $154K | Put options by funds: $316K
52% less capital invested
Capital invested by funds: $16.9M → $8.18M (-$8.76M)
71% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 17
81% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$939K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$333K |
| 3 |
ECM
Element Capital Management
New York
|
+$332K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$155K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$83.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.71M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.32M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$767K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$244K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$228K |
XBIT Hedge Fund Activity: Q2 2018 in Review
31 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2018, worth a combined $8.18M — down 52% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of XBIT and 5 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $939K. The largest seller was BlackRock, cutting an estimated $3.71M.
- 31 institutional investors held XBiotech (XBIT) as of Q2 2018, down from 43 in Q1 2018.
- Funds reported $8.18M of XBiotech stock for Q2 2018, down 52% quarter-over-quarter.
- 5 funds opened new XBiotech positions in Q2 2018 and 17 closed out, a net change of -12 holders.
- The largest XBiotech buyer in Q2 2018 was Millennium Management, an estimated $939K added.
- The largest XBiotech seller in Q2 2018 was BlackRock, an estimated $3.71M sold.
Based on aggregated 13F filings for Q2 2018.